About A public-private partnership that supports the discovery of new medicines through open access research. About SGC Partners Research Laboratories SGC-Toronto SGC-UNC SGC-Frankfurt SGC-Karolinska SGC-Neuro Governance Collaborators Open Science Equity, Diversity and Inclusion Impact Science and Resources Proteins Structure Gallery Expression Vectors Plasmids Constructs Production Protocols ChromoHub Phylogenetic Trees UbiHub Phylogenetic Trees ChemBioPort Chemical Probes Program CHEMICAL PROBES Donated chemical probes Chemical Handles Human Kinase Chemical Probe Program ANTIBODIES TARGET ENABLING PACKAGES (TEPs) TISSUE PLATFORM Open Lab Notebooks Open Chemistry Network PUBLICATIONS People Global Aled Edwards, CEO Susan McCormick, CFO Max Morgan, General Counsel and Public Policy Director SGC Toronto Cheryl Arrowsmith Dalia Barsyte-Lovejoy Takis Prinos Matthieu Schapira Levon Halabelian Rachel Harding SGC UNC Tim Willson Alison Axtman David Drewry Peter J. Brown Rafael M. Couñago SGC UCL Mat Todd SGC Karolinska Michael Sundström Opher Gileadi SGC Frankfurt Stefan Knapp Susanne Müller-Knapp Thomas Hanke Vladimir Rogov Krishnal Saxena Andreas Joerger Václav Němec Andreas Krämer Sandra Röhm SGC Neuro Edward Fon Thomas Durcan Jean-François Trempe Ziv Gan-Or Peter McPherson Carl Laflamme Roxanne Lariviere News & Outreach News & Events News from SGC Press Releases Events Blog Tweets by thesgconline Careers
A public-private partnership that supports the discovery of new medicines through open access research.
SGC6870 A chemical probe for PRMT6Probe and control are available from Sigma. For any inquiries please contact proberequests@thesgc.org.group newOverview SGC6870 SGC6870N A collaboration between the SGC, Eli Lilly, the Icahn School of Medicine at Mount Sinai, and the Ontario Institute for Cancer Research (OICR) has resulted in the discovery of SGC6870, a potent, selective, and cell-active allosteric inhibitor of PRMT6. SGC6870 inhibits PRMT6 with IC50 of 77 ± 6 nM and is selective over all other PRMTs and 23 methyltransferases. SGC6870 inhibits the asymmetric dimethylation of H3R2 by overexpressed PRMT6 in HEK293T cells with an IC50 of 0.8 ± 0.2 microM. SGC6870N is the (S)-enantiomer of SGC6870 and is inactive on PRMT6 and thus an excellent control compound. Data relating to the discovery of this probe is being prepared for publication. In the meantime, in order to facilitate research by the community we are making this compound available through this website.